pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor
Daiichi Sankyo US
Daiichi Sankyo
NovaPharmaNews editorial coverage mentioning Daiichi Sankyo US — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
- Employees
- 4,386
- Programs
- 58
- Drugs
- 66
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Daiichi Sankyo US — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Daiichi Sankyo US — regulatory, clinical, and market analysis.
PMDA approves ENHERTU for HER2-low breast cancer in Japan
PMDA approved ENHERTU for unresectable or metastatic HER2-low breast cancer in Japan, marking a new regulatory catalyst for Daiichi Sankyo and AstraZeneca. The decision expands the drug’s labeled use in a major market and adds another milestone for investors tracking ENHERTU.
AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma
The FDA approved AstraZeneca and Daiichi Sankyo's Datroway (Dato-DXd) as a first-line treatment for triple-negative breast cancer on May 1, 2026. This article provides key takeaways, regulatory details, and strategic implications for pharma decision-makers.
ESMO 2025 Preview: Astra and Daiichi vs. Gilead
As ESMO 2025 approaches, Astra and Daiichi are positioning themselves against Gilead. This article analyzes the implications for investors and pharma teams.
Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes
This article covers significant developments in the pharmaceutical sector, including BMS's $15B deal with Hengrui, Takeda's workforce reductions, and Daiichi's oncology initiatives.